Conrig Pharma
Manufacturing · Denmark · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Conrig Pharma Aps 3, DenmarkWebsite
www.conrigpharma.comRevenue
<$5 MillionIndustry
About Conrig Pharma
Is Conrig Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Conrig Pharma
Product Launch: Get notified when Conrig Pharma launches new products
Earning: See what the market has to say on Conrig Pharma recently announced quarterly report
Click to see if Conrig Pharma had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Conrig Pharma has new funding data
Check out if Conrig Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Conrig Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Conrig Pharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Conrig Pharma as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Conrig Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Conrig Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Conrig Pharma.
Conrig Pharma Tech Stack
A closer look at the technologies used by Conrig Pharma
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Conrig Pharma
Conrig Pharma develops drugs with attractive safety and efficacy profiles to provide new treatments of serious illnesses. Initial focus will be on development of ST-015 for treatment of serious respiratory disorders . ST-015 could enter Phase IIa clinical studies in late 2018.... Read More